Beigene Ltd (NASDAQ:BGNE) CFO Howard Liang sold 10,872 shares of the company’s stock in a transaction that occurred on Friday, March 16th. The shares were sold at an average price of $157.07, for a total value of $1,707,665.04. Following the completion of the transaction, the chief financial officer now directly owns 15,872 shares in the company, valued at approximately $2,493,015.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Howard Liang also recently made the following trade(s):

How to Become a New Pot Stock Millionaire
  • On Monday, March 19th, Howard Liang sold 40,000 shares of Beigene stock. The shares were sold at an average price of $160.27, for a total value of $6,410,800.00.

Shares of Beigene stock opened at $177.22 on Thursday. Beigene Ltd has a 12-month low of $34.36 and a 12-month high of $182.79. The company has a debt-to-equity ratio of 0.23, a current ratio of 6.09 and a quick ratio of 6.02.

Beigene (NASDAQ:BGNE) last issued its quarterly earnings results on Wednesday, February 28th. The company reported ($2.19) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.79) by ($0.40). The company had revenue of $18.17 million during the quarter, compared to analyst estimates of $23.00 million. analysts anticipate that Beigene Ltd will post -7.69 earnings per share for the current year.

BGNE has been the topic of several research reports. Cowen reaffirmed a “buy” rating on shares of Beigene in a research report on Monday, December 11th. BidaskClub downgraded Beigene from a “buy” rating to a “hold” rating in a research report on Saturday, January 13th. Zacks Investment Research downgraded Beigene from a “hold” rating to a “sell” rating in a research report on Monday, January 8th. Ladenburg Thalmann Financial Services reissued a “buy” rating and set a $172.00 price target on shares of Beigene in a research report on Thursday, March 1st. They noted that the move was a valuation call. Finally, Robert W. Baird reissued a “hold” rating and set a $138.00 price target on shares of Beigene in a research report on Thursday, March 1st. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $145.17.

A number of large investors have recently modified their holdings of BGNE. Janus Henderson Group PLC acquired a new stake in shares of Beigene in the 3rd quarter valued at $33,744,000. Artal Group S.A. boosted its holdings in shares of Beigene by 33.3% in the 4th quarter. Artal Group S.A. now owns 300,000 shares of the company’s stock valued at $29,316,000 after purchasing an additional 75,000 shares in the last quarter. California Public Employees Retirement System acquired a new stake in shares of Beigene in the 3rd quarter valued at $4,912,000. Horseman Capital Management Ltd acquired a new stake in shares of Beigene in the 4th quarter valued at $4,515,000. Finally, Employees Retirement System of Texas acquired a new stake in shares of Beigene in the 4th quarter valued at $3,909,000. 51.47% of the stock is currently owned by institutional investors and hedge funds.

WARNING: “Howard Liang Sells 10,872 Shares of Beigene Ltd (BGNE) Stock” was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://www.watchlistnews.com/howard-liang-sells-10872-shares-of-beigene-ltd-bgne-stock/1955361.html.

Beigene Company Profile

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.

Insider Buying and Selling by Quarter for Beigene (NASDAQ:BGNE)

Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.